Lada Nuzhna

AI Summary

→ WHAT IT COVERS Lada Nuzhna and Elliot Hershberg analyze American biotech's competitive disadvantage against China, exploring regulatory barriers, AI's potential impact, and aging research opportunities. → KEY QUESTIONS ANSWERED - Can America compete with China's speed and cost advantages? - Will AI meaningfully reduce drug development costs and timelines? - What structural changes could revive biotech investment returns? - Where will the next trillion-dollar biotech companies emerge? → KEY TOPICS DISCUSSED - China Competition: Chinese biotech leverages investigator-initiated trials and implied approval processes, cutting review timelines five to six times faster than US regulatory pathways. - AI Impact Assessment: Artificial intelligence shows promise in preclinical discovery but faces limitations in addressing phase two efficacy failures and clinical development costs. - Aging Drug Development: GLP-1 medications demonstrate potential as longevity treatments, with Lilly testing semaglutide for Alzheimer's disease beyond traditional metabolic applications. → NOTABLE MOMENT Nuzhna reveals that George Yancopoulos paid ten thousand dollars per patient in Regeneron trials, while current costs have ballooned to five hundred thousand dollars per patient. 💼 SPONSORS None detected 🏷️ Biotech Regulation, China Competition, AI Drug Discovery, Aging Research, Clinical Trials